Clinical Trials

332 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

226 enrolled

Stomach Neoplasms

NCT03221426 2026-03-09

KEYNOTE-585

1,007 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

120 enrolled 17 charts

Phase 1/2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

626 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT03675737 2026-02-27

KEYNOTE-859

1,579 enrolled 31 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Phase 3 Recruiting

550 enrolled

Stomach Neoplasms

NCT07432295 2026-02-25

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Phase 2 Recruiting

180 enrolled

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

40 enrolled 67 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

450 enrolled

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03504397 2026-02-13

Spotlight

565 enrolled 63 charts 3 FDA

Phase 1 Active not recruiting

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

102 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT04421820 2026-01-27

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Phase 1/2 Recruiting

220 enrolled

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Recruiting

555 enrolled

Phase 3 Not yet recruiting

Stomach Neoplasms

NCT06093425 2025-12-17

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

820 enrolled

Stomach Neoplasms

NCT03615326 2025-12-11

MK-3475-811

738 enrolled 22 charts 7 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04363801 2025-10-09

DisTinGuish

Phase 2 Terminated

247 enrolled 38 charts

Phase 2/3 Active not recruiting

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

201 enrolled

Stomach Neoplasms

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

885 enrolled

Stomach Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

74 enrolled

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02872116 2025-08-07

CheckMate649

2,031 enrolled 19 charts 2 FDA

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

71 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT04281576 2024-11-14

Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Phase NA Completed

28 enrolled

Stomach Neoplasms

NCT04933227 2024-11-14

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Phase 2 Terminated

29 enrolled

Stomach Neoplasms

NCT03469557 2024-10-23

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

30 enrolled

Phase 3 Active not recruiting

Esophageal Squamous Cell Carcinoma, Stomach Neoplasms

NCT05144854 2024-09-05

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

626 enrolled

Stomach Neoplasms

NCT03382600 2024-06-11

KEYNOTE-659

100 enrolled 21 charts

Stomach Neoplasms

NCT02746796 2024-05-03

Study of ONO-4538 in Gastric Cancer

Phase 2/3 Completed

680 enrolled

Stomach Neoplasms

NCT03006705 2024-05-03

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

800 enrolled

Stomach Neoplasms

NCT04908813 2024-04-15

Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

150 enrolled

Stomach Neoplasms

NCT06177041 2024-02-28

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Phase 3 Recruiting

486 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

67 enrolled 12 charts

Stomach Neoplasms

NCT06155383 2023-12-14

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 2 Recruiting

90 enrolled

Stomach Neoplasms

NCT01515748 2023-12-13

PRODIGY

530 enrolled 11 charts

Stomach Neoplasms

NCT03745170 2023-03-01

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

650 enrolled

Stomach Neoplasms

NCT01896531 2022-03-02

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

153 enrolled 16 charts

Stomach Neoplasms

NCT02322593 2021-12-20

SOLAR

711 enrolled 16 charts

Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

NCT04859582 2021-12-16

KEYNOTE-859

Phase 3 Withdrawn

BreastGastrointestinalGynecologicHead & NeckThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02545504 2020-05-26

GAMMA-1

432 enrolled 19 charts

Stomach Neoplasms

NCT01748773 2019-10-09

TOXAG

34 enrolled